|Bid||153.29 x 5300|
|Ask||135.00 x 22800|
|Day's Range||144.00 - 146.07|
|52 Week Range||91.62 - 146.15|
|PE Ratio (TTM)||49.57|
|Earnings Date||Feb 14, 2018|
|Forward Dividend & Yield||1.44 (1.36%)|
|1y Target Est||107.45|
Analysts are bullish on these following companies: Class, Imdex, CSL. These companies are relatively strong financially, and have a great outlook in terms of profits and cash flow. Below I’veRead More...
Hizentra PATH study, the largest controlled clinical study in patients with CIDP, met its primary endpoint KING OF PRUSSIA, Pa. , Nov. 9, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring ...
A subgroup analysis of data from the Phase III COMPACT trial showed a 98 percent median reduction in hereditary angioedema (HAE) attacks per month in subjects who experienced at least one attack per week ...
HAEGARDA is the first and only subcutaneous preventive treatment option for hereditary angioedema (HAE) in the United States Oral presentation will highlight the preventive effect of HAEGARDA in type I/II ...
KING OF PRUSSIA, Pa., Oct. 12, 2017 /PRNewswire/ -- CSL Behring is taking its workplace wellness initiatives to a whole new level by providing the American Heart Association's (AHA) Hands-Only™ cardiopulmonary resuscitation (CPR) training to employees. The Hands-Only CPR training program takes about 90 seconds to learn and can mean the difference between life and death for people who experience out-of-hospital cardiac arrest.
TOKYO, Sept. 28, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved AFSTYLA® (hereafter AFSTYLA) [lonoctocog alfa] a recombinant single-chain coagulation factor VIII (rVIII-SingleChain) in patients with haemophilia A (congenital factor VIII deficiency). AFSTYLA is the first and only single-chain recombinant factor VIII product to treat haemophilia A. The single-chain design provides sustained protection from bleeds due to the greater molecular stability and duration of action through a strong affinity with von Willebrand factor (vWF).
CSL Behring's LEAD grant is helping them advocate more effectively in a shifting health care environment. KING OF PRUSSIA, Pa., Sept. 28, 2017 /PRNewswire/ -- The Great Lakes Hemophilia Foundation (GLHF) headquartered in Milwaukee, Wis., the New York City Hemophilia Chapter (NYCHC) and the Ohio Bleeding Disorders Council (OBDC) in Columbus take on complex legislative and public policy issues to ensure patients' voices are heard in their statehouses. Recently they received an added resource in the effort to advocate for patients' rights in the form of CSL Behring's Local Empowerment for Advocacy Development (LEAD) grant.
UNIVERSITY PARK, Pa., Sept. 19, 2017 /PRNewswire/ -- Penn State today announced that CSL Behring, a global specialty biotherapeutics leader, has committed $4.92 million to Penn State over the next six years to create the multidisciplinary Center of Excellence in Biotechnology, and to revitalize the Shared Fermentation Facility, an engine for collaboration and innovation in biological training and research on the University Park campus. Housed within the Huck Institutes of the Life Sciences, the Center of Excellence in Industrial Biotechnology will serve as a unique hub of multidisciplinary teaching and research. The Center will leverage expertise from the Eberly College of Science, and the Colleges of Engineering and Agricultural Sciences at Penn State, while supporting students, faculty and their research.
KING OF PRUSSIA, Pa., Sept. 14, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability. CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage. "The FDA approval of Privigen for CIDP represents a significant milestone for individuals with this debilitating and progressive disease.
Seqirus announced today that the U.S. Food and Drug Administration has approved AFLURIA QUADRIVALENT for use in people five years of age and older, extending the company’s broad portfolio of influenza vaccine offerings.
Immunoglobulin Leader Donates €15,000 to International Patient Organisation to Support Primary Immunodeficiency Awareness Initiatives EDINBURGH, United Kingdom , Sept. 14, 2017 /PRNewswire/ -- Global biotherapeutics ...
As hurricane recovery efforts continue in Texas, the U.S. Department of Health and Human Services , has requested urgent support to help displaced residents fight the onset of influenza.
Annual influenza-related hospitalizations among U.S. children younger than the age of 5 have ranged from 7,000 to 26,000 since 2010, and annual reported influenza-related deaths in children have ranged from 37 to 171 during regular influenza seasons in the same time span, according to the U.S.
Annual influenza-related pediatric hospitalizations in Canada have ranged from about 700 to 1,500 during the last five influenza seasons, and a total of nearly 50 influenza-related paediatric deaths have occurred across that time span, according to the Canadian government.1 One potential solution to reducing these hospitalizations and deaths is with a more effective vaccine for children.
Canadian parents who are educated about immunizing their infants against influenza with an adjuvanted trivalent influenza vaccine see it as a wise, effective, and safe choice.
Categories: Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for CSL Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CSL Ltd. Here are 5 ETFs with the largest exposure to CSL-AU. Comparing the performance and risk of CSL Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
The global biotherapeutics company will to pay $91 million cash and $325 million in milestones to acquire venture-backed Calimmune Inc. and its potential gene therapy for two rare blood disorders.
The acquisition will provide CSL Behring with Calimmune's pre-clinical asset, CAL-H, an HSC gene therapy for the treatment of sickle cell disease and β-thalassemia, which complements CSL Behring's current product portfolio and deep expertise in hematology.
Categories: Yahoo FinanceGet free summary analysis CSL Ltd. reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of CSL Ltd. – Bionomics Ltd (BNO-AU) that have also reported for this period. Highlights Summary numbers: Revenues of AUD 4,302.70 million, Net Earnings of AUD 704.99 million. Gross margins ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis CSL Ltd. reports financial results for the year ended June 30, 2017. We analyze the earnings along side the following peers of CSL Ltd. – Bionomics Ltd (BNO-AU) that have also reported for this period. Highlights Gross margins widened from 48.03% to 50.91% compared to the same period last year, operating ... Read more (Read more...)
Rating Action: Moody's takes rating action on CSL Limited. Global Credit Research- 16 Aug 2017. Sydney, August 16, 2017-- Moody's Investors Service has today assigned a first-time issuer rating of A3 to ...
Berinert® Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients